Drug
Peginterferon Alfa 2A Pegasys
Peginterferon Alfa 2A Pegasys: highest development phase Post-Market, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| peginterferon alfa-2a [Pegasys] NCT01429792 | Post-Market | Hepatitis C, Chronic |
Latest
No recent events.
Follow Peginterferon Alfa 2A Pegasys on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.